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The impact of neonatal androgen receptor (AR) stimulation/blockage, due to testosterone propionate (TP)/AR antagonist treat-
ment, on individual anthropometry and neuroendocrine-metabolic function was evaluated in the juvenile female rat. Pups (age
5 days) were s.c. injected with TP (1.25mg), flutamide (F; 1.75mg), and TP+ F or vehicle (control, CT) and studied on day 30 of
age. Body weight (BW), parametrial adipose tissue (PMAT) mass, food intake, adipoinsular axis, and steroidogenic functions were
examined. Opposite to TP-rats, F-treated rats developed hypophagia, grew slowly (BW and PMAT), and displayed heightened
peripheral insulin sensitivity. These F effects were abrogated in TP+ F animals. Accordingly, TP rats displayed hyperleptinemia,
an effect fully prevented by F cotreatment. Finally, androgen-treated animals bore an irreversible ovarian dysfunction (reduced
circulating levels of 17HOP4 and ovary 17HOP4 content and P450c17mRNA abundance).These data indicate that early stimulation
of AR enhanced energy store, blockage of AR activity resulted in some beneficialmetabolic effects, and neonatally androgenized rats
developed a severe ovarian dysfunction. Our study highlights the important role of AR in the early organizational programming of
metabolic and neuroendocrine functions.
1. Introduction
Intrauterine and early postnatal endogenous and exogenous
environments all have an important role for normal meta-
bolic-neuroendocrine functions and neuronal development
of the offspring [1]. Fetal sexual differentiation results from
complex interplay between genetic and hormonal factors
[2, 3], and testosterone playing a key role in these associated
events is supported by the fact that excess testosterone in
female fetuses results in functional, behavioral, and morpho-
logical defects in adulthood [2, 4, 5]. Insulin resistance is
frequently associated with hyperandrogenemia, and clinical
studies suggest that interaction between insulin and sex
hormones takes place in healthy subjects [6]. Moreover,
Barraclough CA [7] reported that just a single neonatal s.c.
treatment with testosterone propionate (TP) in the female
rat produces several metabolic and clinical features of the
human polycystic ovary syndrome (PCOS). Moreover, we
previously reported that transient androgenization in normal
female rats at neonatal [8] or early postpubertal [9] ages
did result in a seriously disrupted metabolic phenotype [10]
accompanied by impaired peripheral and adipose tissue (AT)
insulin sensitivity in adulthood.
Since biological active androgens exert their effects
through binding to androgen receptor (AR) [11], the present
study explored whether neonatal manipulation of AR func-
tion in normal female rat could alter metabolic and neu-
roendocrine functionswhen individuals reached juvenile age.
For this objective, rats were neonatally treated with either
testosterone [7], the nonsteroidal anti-AR flutamide [12], or
both compounds in combination and then studied at 30 days
of age.
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2. Materials and Methods
2.1. Experimental Animals. Onday 5 of age, female rats (Spra-
gue-Dawley; 𝑛 = 12/16 per group obtained from 3-4 different
litters) were s.c. injected with either 50𝜇L of sterile corn
oil alone (control; CT) or 1.25mg of testosterone propionate
(TP) [8], 1.75mg flutamide (F) [13], or both (TP+ F). Rats
were checked daily (between days 7 and 30 of age) for
vaginal opening. After weaning (age 21 days), rats were
individually housed, and body weight (BW) and food intake
were recorded daily (07:30–08:30 h) up to the experimental
day (30 days of age). Animals were kept in a light (lights on
07:00 to 19:00 h) and temperature (22∘C) controlled room.On
the experimental day, animals were euthanized in nonfasting
condition, and trunk blood was collected. Parametrial adi-
pose tissue (PMAT) pads, adrenal glands (AGs), and ovaries
were quickly dissected, weighed, and either homogenized
or kept frozen (−80∘C). Experiments followed international
regulations concerning the ethical use of animals and were
also approved by our Animal Care Committee.
2.2. Metabolite Measurements. Plasma glucose (Wiener Ar-
gentina Lab.) and triglyceride (TG; Wiener) levels were
determined by commercial kits. Circulating leptin [14],
insulin [9], testosterone [15], 17𝛽-estradiol (E2) [15], 5𝛼-
androstane-3𝛼, 17𝛽-diol (5𝛼Diol) [16], and corticosterone
[14] concentrations were determined by specific radioim-
munoassays (RIAs) developed in our laboratories. (FULL
TERM FIRST) HOMA values were calculated as [glucose
(mg/dL) × insulin (ng/mL)]/405. Plasma levels of 17𝛼-
hydroxy-progesterone (17HOP4) were assayed by a commer-
cial RIA kit (IMMUNOTECH SAS, France; standard curve
ranging between 0.05–50 ng/mL; coefficients of variation
intraassay and interassay were 7-8 and 5–15%, resp.). Tissues
(AGs and ovaries) were either homogenized in a small vol-
ume (200–300𝜇L) of 0.01MHCl or kept frozen (−80∘C) until
assayed. The 10,000×g supernatants of tissue homogenates
were then assayed for measurement of corticosterone (AGs)
and 17HOP4 (AGs and ovaries), and values were expressed as
mass of steroid per mg of protein (Wiener Lab.).
2.3. Ovary RNA Isolation and Real-Time Quantitative PCR.
Total RNA was isolated from ovaries of different groups
by the single-step, acid guanidinium isothiocyanate-phenol-
chloroform extractionmethod (Trizol; Invitrogen, Life Tech.,
USA; cat. # 15596-026) [17]. One𝜇g of total RNAwas reverse-
transcripted using random primers (250 ng) and Superscript
III Rnase H-Reverse Transcriptase (200U/𝜇L Invitrogen,
Life Tech, USA; cat. # 18989-093). Primers applied: 𝛽-actin
(ACTB) (R): 5󸀠-ACCCTCATAGATGGGCACAG-3󸀠, (F):
5󸀠-AGCCATGTACGTAGCCATCC-3󸀠 (115 pb) [GenBank
Accession Number (GBAN): NM 031144] and cytochrome
P450, family 17, subfamily A, polypeptide 1 (P450c17) (R):
5󸀠-GGCCACGCCTTTCCCTTGGT-3󸀠, (F): 5󸀠-AGCTGG-
CCAGGGAGGTGCTC-3󸀠 (101 pb) (GBAN: NM 012753.1).
Two 𝜇L of the reverse transcription mix was amplified with
QuantiTect Syber Green PCR kit (Qiagen, cat. # 204143)
containing 0.5 𝜇M of each specific primer, using LightCycler
Detection System (MJMini Opticon, Biorad). PCR efficiency
was∼1.Threshold cycles (Ct)weremeasured in separate tubes
by duplicate. Identity and purity of the amplified product
were checked by electrophoresis on agarose minigels, and the
melting curve was analyzed at the end of amplification. The
differences between the cycle threshold (Ct) were calculated
in every sample for each gene of interest as follows: Ct gene
of interest-Ct reporter gene. 𝛽-actin, whose mRNA levels did
not differ comparing control to test groups, was the reporter
gene. Relative changes in expression level of one specific gene
(ΔΔCt) were calculated as ΔCt of the test groupminus ΔCt of
the control group and then presented as 2−ΔΔCt.
2.4. Statistical Analysis. Data (means± SEM) were analyzed
by multiple-way ANOVA, followed by post hoc comparisons
with Fisher’s test or the nonparametric Mann-Whitney test
[18]. 𝑃 values under 0.05 were considered statistically differ-
ent.
3. Results
3.1. Anthropometric Parameters
3.1.1. BodyWeight and Adipose TissueMass. All experimental
animals had comparable body weights at weaning [age 21
days; 30.46 ± 0.79, 31.56 ± 1.06, 29.65 ± 1.27 and 32.66 ± 1.57 g
in CT (𝑛 = 12), TP (𝑛 = 16), F (𝑛 = 12) and TP + F (𝑛 = 16)
groups, resp.]. On experimentation (age 30 days), F rats were
the lightest (52.63 ± 1.95 g; 𝑃 < 0.05 versus 58.75 ± 1.49 g in
CT) and TP animals were the heaviest (63.38±1.22 g;𝑃 < 0.05
versus CT), whereas BW values for TP+ F rats (60.59±0.72 g)
only significantly (𝑃 < 0.05) differed from those of F group.
No significant group differences in the slopes of growth
curves were observed (data not shown); however, the curve
displayed by F-treated rats was somewhat displaced to the
right, and, conversely, that of TP-treated rats was somewhat
displaced to the left (Figure 1(a)). Concordantly, the 9-day
body weight catch-up (calculated between 21 and 30 days
of age) was significantly (𝑃 < 0.05) lower in F (22.97 ±
1.11 g) than in CT (28.11 ± 0.78 g) rats, whereas those in
TP (30.04 ± 1.01 g) and TP+ F (27.93 ± 1.03 g) rats did
not differ significantly from CT values. On the experimental
day, only androgen-treated rats (TP and TP+ F) displayed
an open vagina; however, androgenized rats cotreated with
F displayed a significant delay in the vaginal opening day (on
17 ± 0.9 days of age) compared to rats treated with TP alone
(11.5±1.5 days of age; 𝑃 < 0.05). Individual PMAT padmass
was enlarged in TP rats (167.4±8.3 versus 147.8±9.7mg/100 g
BW in CT rats; 𝑃 < 0.05) and reduced in F-treated animals
(112.3 ± 8.5mg/100 g BW; 𝑃 < 0.05 versus CT); interestingly,
this F effect was no longer observed when animals were
cotreated with androgen (TP+ F rats: 141.46 ± 13.5mg/100 g
BW).
3.1.2. Food Intake. Individual daily food intake (Figure 1(b))
was significantly (𝑃 < 0.05) lower in F rats (9 day-average:
6.01 ± 0.22 g/day) than in the remaining groups (7.01 ± 0.39,
7.14 ± 0.44, and 7.27 ± 0.29 g/day in CT, TP, and TP+ F rats,
resp.). Because of differences found in individual BW values
of F-treated rats, the 9 day-average daily food intake was nor-
malized by day after day change in rat BW and expressed in
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Figure 1: Changes in bodyweight (BW) (a) and food intake (b) in different groups of neonatally-treated rats, examined daily betweenweaning
(age 21 days) and experimentation (age 30 days). Values are means± SEM, 𝑛 = 12/16 rats per group. ∗𝑃 < 0.05 versus CT values.
g/day/100 g BW. Data indicated that, although no differences
were found between CT and TP/TP+ F values, this difference
in daily food intake remained the same in flutamide-treated
rats: 16.34 ± 0.56 and 14.92 ± 0.35 g/day/100 g BW in CT and
F animals, respectively (𝑃 < 0.05).
3.2. Adipoinsular Axis Activity. While triglyceridemia was
not modified by either neonatal treatment (Figure 2(a));
conversely, circulating leptin levels were enhanced in TP (𝑛 =
7) rats (𝑃 < 0.05 versus CT values, 𝑛 = 6), an increase
fully abolished by F cotreatment (TP + F group, 𝑛 = 7)
(Figure 2(b)). Plasma glucose levels were similar in all groups
studied (Figure 2(c)). Whereas insulinemia remained at CT
level in TP animals (Figure 2(d)), plasma insulin concentra-
tion was significantly (𝑃 < 0.05 versus CT values) reduced in
F-treated animals (𝑛 = 6), an effect fully abolished if F rats
were cotreated with androgen (TP+ F group) (Figure 2(d)).
Tallying with the latter data, HOMA values were significantly
(𝑃 < 0.05) reduced in F-treated rats (0.131±0.008) compared
to those fromCT rats (0.183±0.018).Theflutamide-enhanced
insulin sensitivity (low HOMA score) was severely impaired
by TP cotreatment (TP + F rats: 0.236 ± 0.033; 𝑃 < 0.05
versus F values). HOMA score remained normal in TP rats
(0.189 ± 0.017).
3.3. Steroidogenic Function. With respect to corticoadrenal
steroid contribution to the periphery, plasma, and AG cor-
ticosterone concentrations were similar in all groups (data
not shown), and results were concordant with those obtained
in isolated fasciculata-reticularis enriched cells incubated
in vitro in absence or presence of ACTH (data not shown).
Interestingly, the steroidogenic pathway seems to be altered
at the ovarian level in animals having received androgen
treatment (TP and TP+ F groups; 𝑛 = 7 rat per group);
indeed, they displayed reduced (𝑃 < 0.05 versus CT rats, 𝑛 =
6 rats) 17HOP4 plasma concentrations (Figure 3(a)), whereas
in F-treated animals (𝑛 = 6) the peripheral level of this steroid
remained normal (Figure 3(a)). Regarding androgens, plasma
testosterone and 17𝛼Diol concentrations were not modified
by neonatal TP treatment (Figures 3(b) and 3(c), resp.). Con-
versely, while neonatal F treatment did notmodify circulating
testosterone levels (Figure 3(b)), it significantly (𝑃 < 0.05
versus CT values) enhanced 5𝛼Diol plasma concentrations
(Figure 3(c)); however, this effect was fully counteracted
by androgen cotreatment (TP + F animals) (Figure 3(c)).
Peripheral E2 concentrations were significantly enhanced in
F rats (𝑃 < 0.05 versus CT values), an effect fully abolished
by TP cotreatment (Figure 3(d)).
The results of peripheral 17HOP4 levels agreed with data
from measurements of 17HOP4 content in ovaries. Indeed,
adrenal gland 17HOP4 content was detected at a very low
level in all groups, with no differences among them (data
not shown); conversely, in ovaries very significant differences
were found (Figure 4(a)). TP-treated rats (𝑛 = 5) either
cotreated or not with F displayed a reduced (𝑃 < 0.05 versus
CT values, 𝑛 = 4) 17HOP4 ovary content (Figure 4(a)).
Conversely, F treatment (𝑛 = 4) by itself did not modify the
ovarian concentration of 17HOP4 (Figure 4(a)). As expected,
no P450c17 mRNA was detected in any adrenal gland exam-
ined (data not shown). Consequently, ovary P450c17 mRNA
abundance was significantly (𝑃 < 0.05 versus CT levels)
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Figure 2: Circulating levels of triglycerides (a), leptin (b), glucose (c), and insulin (d) in different groups of juvenile rats. Values are
means± SEM (𝑛 = 6/7 rats per group). ∗𝑃 < 0.05 versus CT values.
reduced in ovaries from both TP and TP+ F rats, whereas it
remained at CT expression level in ovarian tissues from F rats
(Figure 4(b)).
4. Discussion
The present study supports that neonatal modifications in
androgen bioactivity clearly impacted on the organization
of several metabolic and neuroendocrine functions when
female rats reached juvenile age.This clearly indicates that not
only the neonatal androgen excess but also a lack of full func-
tionality of AR is involved in the physiological programming
of the organism [19, 20].
Two opposite approaches were used here to contemplate
that AR is one of the structures that plays a pivotal role in
the metabolic programming of the organism. Indeed, several
authors including our group have demonstrated the delete-
rious effects of neonatal androgen excess in the physiology
of the adult female rat [8, 10, 19, 21]. On the other hand,
early (pre-/postnatal) flutamide intervention has been used
to test the long-term effect of lack of full AR function in
adult rats [13, 22, 23]. We must mention that the efficacy of
flutamide, a nonsteroidal pure anti-AR [12], has largely been
proved through its therapeutic effect to mitigate androgen-
dependent prostate cancer [12, 24].
We presently found that, whereas flutamide-treated rats
grew slowly, expectedly, androgen-treated rats grew faster
[24] and that the androgen effect was corrected, at least in
part, when rats were cotreated with flutamide.This androgen
effect appeared to act through its anabolic activity [24].
Interestingly, animals with retarded growth (F rats) are char-
acterized by hypophagia, thus evidencing a physiological
orexigenic activity of endogenous androgen [25]. Moreover,
we found that the hypophagia developed by flutamide-
treated rats was no longer observed after cotreating animals
with androgen (TP+ F rats), thus clearly indicating an AR-
mediated effect.
New data on the neonatally androgenized rat model at
juvenile age are provided here. Among these and compared
to normal littermate rats, we observed (a) early disruption
in the adipo insular axis function such as enhanced PMAT
mass and hyperleptinemia while still managing carbohydrate
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Figure 3: Circulating levels of 17 hydroxy-progesterone (a), testosterone (b), 5𝛼-androstane-3𝛼, 17𝛽-diol (c), and 17𝛽-estradiol (d) in different
groups of juvenile rats. Values are means± SEM (𝑛 = 6/7 rats per group). ∗𝑃 < 0.05 versus CT values.
(glycemia) and lipid (triglyceridemia) metabolism and (b)
ovarian dysfunction. These findings indicate that, compared
to the adult stage, at juvenile age the deleterious metabolic
effect of early transient hyperandrogenization is not yet fully
developed (e.g., enhanced triglyceridemia and insulinemia)
[10].
We also observed that PMATpadmass was enhanced and
lowered by testosterone and flutamide treatments, respec-
tively; remarkably, the individual effect of either compound
was absent when administered to rats in a combinedmanner.
Once again, these observations strongly argue in favor of the
accepted testosterone effect on adipose tissue mass. Indeed,
hyperadiposity [8–10, 19, 21] seems to be developed by
transient hyperandrogenemia, even when examining region-
alized fat depots. For instance, increased visceral and mesen-
teric fatnesses were reported in neonatally androgenized rats
[8, 19] as well as in PM fat pads [10, 21]. Now demonstrated
by both designs: androgen excess (TP rats) and androgen-
bioactivity defect (F rats). Further, concordant with data
from PMAT mass, neonatal androgenization also resulted in
juvenile animals, as in older ones [10], with high leptinemia.
We previously demonstrated that transient high concentra-
tions of testosterone clearly induce a spontaneous increase
in leptin secretion by adipocytes isolated from normal adult
female rats [9]. Importantly, as observed in adipose tissue
pad mass, enhancement in peripheral leptin levels induced
by neonatal androgen treatment was fully prevented by AR-
blocker cotreatment. These data suggest an androgen, AR-
mediated effect on the endocrine function of adipose tissue.
As mentioned above, whereas lipidic and glucose home-
ostases were not affected by any neonatal treatment, other
parameters examined revealed that animals neonatally
blocked from AR functionality revealed improved peripheral
insulin sensitivity (e.g., low insulinemia and HOMA values);
however, this beneficial metabolic effect was no longer
observed when animals received androgen and flutamide
in cotreatment. These data fully support the concept that a
sex steroid (androgen) basis is highly involved in the later
development of clinical states (such as in human PCOS) of
impaired insulin sensitivity dependent on early hyperandro-
genism [26, 27]. Nevertheless, it must be pointed out that
in favor of the metabolic advantage induced by flutamide
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Figure 4: Ovarian concentration of 17 hydroxy-progesterone (a) and cytochrome P450, family 17, subfamily A, polypeptide 1 (b) mRNA in
different groups of experimental rats. Values are means± SEM (𝑛 = 4/5 ovaries per group). ∗𝑃 < 0.05 versus CT values.
treatment this was part of a phenotype characterized by
reduced food intake and body weight.
Finally, whereas peripheral testosterone concentrations
were not affected by any neonatal treatment, increased
peripheral levels of testosteronemetabolites [28], 5𝛼Diol, and
E2 were found in F-treated rats. The latter changes were
fully prevented by TP cotreatment. Although steroidogenic
adrenal functionwas notmodified by any neonatal treatment,
conversely, only neonatally androgenized rats displayed a
drastic reduction in 17HOP4 plasma concentrations. Con-
cordantly, reduced ovary but not adrenal 17HOP4 concen-
tration was found in these rats. Confirmation of these data
was the finding of diminished P450c17 mRNA expression
level in these ovaries. To our knowledge, this is the first
report addressing impaired ovary P450c17 activity due to
neonatal androgenization in the juvenile rat.
5. Conclusions
Neonatal manipulation of AR function in the female rat by
either androgen excess or AR-blockage impacted on individ-
ual metabolic-neuroendocrine programming. These modifi-
cations seem to be perpetuated and even aggravated once rats
reach reproductive age [8, 10]. Indeed, AR-blocker therapy
by itself ameliorated several metabolic functions and, when
used as cotreatment, prevented several dysfunctions induced
by hyperandrogenemia. Thus, a safe antiandrogen therapy
could be used in pregnant women displaying hyperandrogen-
emia/hyperandrogenism [26, 27] for further prevention of
newborn’smiss-programming.However, in spite of the severe
ovarian dysfunction induced by neonatal hyperandrogene-
mia, it remains to be further investigated whether flutamide
is fully able to cross the blood brain barrier [29] and whether
the deleterious androgen excess impact on the reproductive
axis is truly irreversible [30].
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